Top faculty in cardiometabolic medicine to headline annual WCIRDC meeting
Click Here to Manage Email Alerts
Key takeaways:
- The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease begins Dec. 12 in Los Angeles.
- The conference targets multiple specialties, with research spanning basic and clinical science.
Presentations on the latest cardiometabolic research, panel discussions and meet-the-expert sessions are among this year’s highlights of the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), a global meeting dedicated to diabetes, obesity, lipids, cardiovascular-renal and liver disease, will kick off on Dec. 12 and continue through Dec. 14. This year marks the 22nd annual meeting, which will take place in-person at Hilton Universal City in Los Angeles.
“Attendees of this meeting get the top faculty in the U.S. and internationally,” Yehuda Handelsman, MD, FACP, FNLA, FASPC, FAHA, MACE, chair of WCIRDC and medical director and principal investigator of the Metabolic Institute of America in Tarzana, California, told Healio. “These people are leaders in their fields and are faculty of the large professional societies like the American College of Cardiology, the American Heart Association and the American Diabetes Association — all here in one place. You can meet and speak with them face to face during the session breaks. Everyone gets exposed to the best thought leaders in these fields, and the most up-to-date information.”
WCIRDC will feature 21 sessions examining a wide range of topics across cardiology, endocrinology, nephrology and primary care, along with live debates. Among the sessions at this year’s meeting will be an update to the Multispecialty Practice Recommendations for the Management of Diabetes, Cardiorenal and Metabolic Diseases (DCRM 2.0), which were first presented during the 2021 WCIRDC meeting. The guidance was designed to give clinicians easy-to-follow recommendations for treating common cardiometabolic and renal conditions, with the updated guidance more applicable to health care providers around the world, Handelsman said.
Other featured presentations include:
A session on the association between circadian rhythm and cardiorenal metabolic disease, with lectures on the circadian clock with Bart Staels, PhD, and practical insights into circadian medicine as the fourth dimension of CV health and disease with Michael J. Sole, MD “We have done a lot on circadian rhythm over the years but this is the first time we have Michael Sole presenting on this topic,” Handelsman told Healio.
A technology and health session with lectures on long-term patterns with real-world continuous glucose monitoring by Peter D. Reaven, MD, and the use of CGM for metabolic subphenotyping with Tracey L. McLaughlin, MD, MS.
“Sarcopenia’s association with obesity — myth and reality” will be debated by Samuel Klein, MD, and Healio | Endocrine Today Co-Editor Richard E. Pratley, MD “All of this is connected to a new era of weight loss, where researchers are looking into not just amount of weight lost, but the quality of weight loss,” Handelsman told Healio. “This is the first time this issue is being discussed.”
Late-breaking scientific data will also be presented, including new phase 2 data on maridebart cafraglutide (MariTide, Amgen), a monthly injectable GIP receptor agonist/GLP-1 receptor agonist studied in people with overweight and obesity, and final results from the CATALYST study on hypercortisolism in difficult to control diabetes.
The Gerald Reaven Distinguished Leader in Insulin Resistance Award will be presented to W. Timothy Garvey, MD, FACE, MABOM, endocrinologist and professor at the University of Alabama (UAB) at Birmingham and principal investigator of the UAB Diabetes Research Center. Garvey will discuss the “belated pathway toward obesity medicine,” highlighting the latest drug developments. “People connect Dr. Garvey with obesity, but he has been a huge researcher in carbohydrate metabolism and insulin resistance over the years,” Handelsman told Healio.
Each session will be followed by a live Q&A and discussion on implications for clinical practice. Each day will also end with a 1-hour live panel discussion to provide a summary of the day and commentary.
This year’s meeting also features an exhibit hall, poster session and oral abstract presentations. Abstracts presented at the meeting will also be published in the journal Metabolism.
“Our motto is: ‘Tomorrow’s clinical science, today,’” Handelsman told Healio. “This conference is a marriage of basic translational science and clinical science. We have a lot for clinicians and researchers. Every lecture is designed specifically for this meeting.”
WCIRDC is an in-person meeting only. Attendees have the option to purchase 90 days of on-demand recordings with access to sessions videos, abstracts and more.
Healio is an official media partner of WCIRDC. The Healio team will provide coverage from WCIRDC, with reports on the presentations and researcher perspectives.
For more information on the WCIRDC agenda and registration, visit www.wcir.org.
Collapse
Healio Interviews
Click Here to Manage Email Alerts